[go: up one dir, main page]

CY1105863T1 - Παραγωγα εποθιλονης και η συνθεση και η χρηση τους - Google Patents

Παραγωγα εποθιλονης και η συνθεση και η χρηση τους

Info

Publication number
CY1105863T1
CY1105863T1 CY20061101818T CY061101818T CY1105863T1 CY 1105863 T1 CY1105863 T1 CY 1105863T1 CY 20061101818 T CY20061101818 T CY 20061101818T CY 061101818 T CY061101818 T CY 061101818T CY 1105863 T1 CY1105863 T1 CY 1105863T1
Authority
CY
Cyprus
Prior art keywords
absent
single bond
alkyl
double bond
bond
Prior art date
Application number
CY20061101818T
Other languages
English (en)
Inventor
Kyriacos Costa Nicolaou
Nigel Paul King
Maurice Raymond Verschoyle Finlay
Yun He
Frank Roschangar
Dionisios Vourloumis
Hans Vallberg
Antony Bigot
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1105863T1 publication Critical patent/CY1105863T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αφορά ανάλογο εποθιλόνης που απεικονίζεται από τον τύπο (I) όπου (i) R2 είναι ανύπαρκτο ή οξυγόνο, "a" μπορεί να είναι είτε μονός είτε διπλός δεσμός, "b" μπορεί να είναι είτε ανύπαρκτο ή μονός δεσμός και "c" μπορεί να είναι είτε ανύπαρκτο ή μονός δεσμός, υπό την προϋπόθεση ότι εάν το R2 είναι οξυγόνο τότε "b" και "c" είναι και τα δύο ένας μονός δεσμός και "a" είναι ένας μονός δεσμός, εάν R2 είναι ανύπαρκτο τότε "b" και "c" είναι ανύπαρκτα και "a" είναι δυτλός δεσμός, και εάν "a" είναι διπλός δεσμός, τότε R2, "b" και "c" είναι ανύπαρκτα, R3 είναι μια ρίζα που επιλέγεται από την ομάδα που αποτελείται από υδρογόνο, χαμηλότερο αλκύλιο, -CH=CH2, -CCH, -CH2F, -CH2Cl, -CH2-OH, -CH2-O-(C1-C6-αλκύλιο) και -CH2-S-(C1-C6-αλκύλιο), R4 και R5 επιλέγονται ανεξάρτητα από υδρογόνο, μεθύλιο ή μια ομάδα προστασίας και R1 είναι όπως ορίζεται στην περιγραφή, ή ένα άλας της ένωσης του τύπου (I) όπου υφίσταται ομάδα σχηματισμού άλατος. Μια περαιτέρω πτυχή της εφεύρεσης σχετίζεται με τη σύνθεση εποθιλόνης Ε. Οι ενώσεις αυτές εμφανίζουν μεταξύ άλλων δραστηριότητα αναστολής αποπολυμερισμού μικροσωληνίσκων και είναι π.χ. χρήσιμες κατά των εκφυτικών νόσων.
CY20061101818T 1998-06-22 2006-12-20 Παραγωγα εποθιλονης και η συνθεση και η χρηση τους CY1105863T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs
PCT/EP1999/004287 WO1999067252A2 (en) 1998-06-22 1999-06-21 Epothilone derivatives and their synthesis and use

Publications (1)

Publication Number Publication Date
CY1105863T1 true CY1105863T1 (el) 2011-02-02

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101818T CY1105863T1 (el) 1998-06-22 2006-12-20 Παραγωγα εποθιλονης και η συνθεση και η χρηση τους

Country Status (27)

Country Link
US (3) US6380394B1 (el)
EP (2) EP1089998B1 (el)
JP (1) JP4681732B2 (el)
KR (3) KR20080045298A (el)
CN (1) CN1192031C (el)
AT (1) ATE343573T1 (el)
AU (1) AU757854B2 (el)
BR (1) BR9911420A (el)
CA (1) CA2334342C (el)
CY (1) CY1105863T1 (el)
CZ (1) CZ301783B6 (el)
DE (1) DE69933767T2 (el)
DK (1) DK1089998T3 (el)
ES (1) ES2273502T3 (el)
HU (1) HUP0102711A3 (el)
ID (1) ID28210A (el)
IL (3) IL139784A0 (el)
MX (1) MXPA00012443A (el)
NO (1) NO328417B1 (el)
NZ (1) NZ508622A (el)
PL (1) PL197648B1 (el)
PT (1) PT1089998E (el)
RU (1) RU2227142C2 (el)
SK (2) SK287864B6 (el)
TR (1) TR200003844T2 (el)
WO (1) WO1999067252A2 (el)
ZA (1) ZA200007059B (el)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186606B2 (de) 1995-11-17 2011-09-07 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate, ihre Herstellung und Verwendung
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19820599A1 (de) * 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
JP4662635B2 (ja) 1998-11-20 2011-03-30 コーサン バイオサイエンシーズ， インコーポレイテッド エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
ATE254615T1 (de) * 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
TR200102969T2 (tr) 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2001038317A2 (en) * 1999-11-24 2001-05-31 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Fungicidal melithiazole derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
BR0114065A (pt) * 2000-09-22 2003-07-22 Biotechnolog Forschung Gmbh Triazolo-epotilonas
JP2005500974A (ja) * 2000-10-13 2005-01-13 ザ ユニバーシテイ オブ ミシシッピー エポシロン類及び関連類似体の合成
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EP1938821B1 (en) 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
MXPA03006485A (es) 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
EE200300397A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
DE60213884T2 (de) * 2001-02-27 2007-02-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von Epothilonen
ES2384789T3 (es) 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
BR0212107A (pt) * 2001-08-23 2004-08-24 Novartis Ag Análogos da ciclopropil e da ciclobutil epotilona
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
NZ532418A (en) * 2001-10-25 2007-02-23 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent
AU2002361022A1 (en) * 2001-12-07 2003-06-17 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
CA2471509A1 (en) 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE60318224T2 (de) * 2002-08-02 2009-01-29 Novartis Ag Epothilonderivate
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DK1506203T3 (da) * 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
CA2499600C (en) 2002-09-23 2012-08-21 Daniel Benigni Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
CA2501717C (en) * 2002-10-15 2012-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
US8003801B2 (en) * 2005-11-22 2011-08-23 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
CA2671492A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
JP2010518123A (ja) 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
US8435983B2 (en) * 2007-03-23 2013-05-07 The University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
JP2011526601A (ja) * 2008-07-03 2011-10-13 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性化合物
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
US9862692B2 (en) * 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202775A1 (en) 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
US10874646B2 (en) * 2015-10-16 2020-12-29 William Marsh Rice University Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW221441B (el) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP1186606B2 (de) 1995-11-17 2011-09-07 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate, ihre Herstellung und Verwendung
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Also Published As

Publication number Publication date
EP1089998B1 (en) 2006-10-25
IL182744A0 (en) 2007-07-24
NZ508622A (en) 2003-07-25
HUP0102711A2 (hu) 2001-12-28
KR20090066332A (ko) 2009-06-23
CZ301783B6 (cs) 2010-06-23
JP4681732B2 (ja) 2011-05-11
WO1999067252A2 (en) 1999-12-29
MXPA00012443A (es) 2004-12-03
SK19712000A3 (sk) 2001-09-11
EP1741715A1 (en) 2007-01-10
CN1192031C (zh) 2005-03-09
SK287864B6 (sk) 2012-02-03
IL139784A (en) 2010-05-17
IL182744A (en) 2010-05-17
KR100864742B1 (ko) 2008-10-22
CZ20004769A3 (cs) 2001-07-11
KR20080045298A (ko) 2008-05-22
AU4774899A (en) 2000-01-10
US20030203938A1 (en) 2003-10-30
DE69933767T2 (de) 2007-09-13
NO20006378L (no) 2001-02-21
PT1089998E (pt) 2007-01-31
JP2002518504A (ja) 2002-06-25
US6531497B1 (en) 2003-03-11
DK1089998T3 (da) 2007-01-15
PL345327A1 (en) 2001-12-17
CN1306531A (zh) 2001-08-01
BR9911420A (pt) 2001-03-20
EP1089998A2 (en) 2001-04-11
HK1038358A1 (en) 2002-03-15
AU757854B2 (en) 2003-03-06
NO328417B1 (no) 2010-02-15
HUP0102711A3 (en) 2002-09-30
ZA200007059B (en) 2002-01-30
IL139784A0 (en) 2002-02-10
KR20010083060A (ko) 2001-08-31
DE69933767D1 (de) 2006-12-07
CA2334342A1 (en) 1999-12-29
TR200003844T2 (tr) 2001-04-20
CA2334342C (en) 2012-07-17
WO1999067252A3 (en) 2000-03-16
NO20006378D0 (no) 2000-12-14
RU2227142C2 (ru) 2004-04-20
SK285647B6 (sk) 2007-05-03
US7579366B2 (en) 2009-08-25
ID28210A (id) 2001-05-10
ATE343573T1 (de) 2006-11-15
ES2273502T3 (es) 2007-05-01
PL197648B1 (pl) 2008-04-30
US6380394B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
CY1105863T1 (el) Παραγωγα εποθιλονης και η συνθεση και η χρηση τους
ATE250573T1 (de) Azetidin- und pyrrolidinderivate
ATE207488T1 (de) Heterozyklische verbindungen mit antidiabetischer wirkung, ihre herstellung und verwendung
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
FI980175L (fi) 2-sulfonamidofenonijohdannaisia
FI881985A0 (fi) Foerfarande foer framstaellning av terapeutiskt verkande (s,s,s)-isomerer av substituerade acylderivat av 1,2,3,4-tetrahydroisokinolin-3-karboxylsyror.
NO934833D0 (no) Thiazolidinedionderivater, deres fremstilling og anvendelse
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
DK0565721T3 (da) 1,4-Benzothiazepinderivat
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
ATE109770T1 (de) Derivate der coffeinsäure und pharmazeutische zusammensetzungen, die sie enthalten.
ATE118770T1 (de) Thiazolidinone und oxazolidenonederivate, ihre herstellung und ihre anwendung als vasodilatatoren.
ATE504572T1 (de) Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
DE60037766D1 (de) Verfahren zur Herstellung von 2-Alkyl-3-aminothiophen Derivate und 3-Aminothiophen Derivate
DE69201184D1 (de) 5- Piperazinylalkyl-1,5-Benzothiazepinone verwendbar als Calciumantagonisten.
FI956151A0 (fi) Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia
ATE146481T1 (de) Epoxysuccinamidsäurederivat
NO921282L (no) Benzotiazolderivater og deres anvendelse
ATE105565T1 (de) Pradimicinderivate.
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.